Publication | Closed Access

Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain

Antimicrobial StewardshipAntibioticsHealth EconomicsEconomic AssessmentClostridium Difficile InfectionHealthcare-associated InfectionHospital EpidemiologySpecial PopulationsInfection ControlMedicineClinical MicrobiologyAntimicrobial ResistanceHealth Sciences